This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sinclair, C. S. Articles by Couch, F. J. Search for Related Content PubMed PubMed Citation Articles by Sinclair, C. S. Articles by Couch, F. J.

BRCA1 and BRCA2 Have a Limited Role in Familial Prostate Cancer¹

Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota, 55905

Epidemiological studies have suggested that the breast cancer susceptibility genes, BRCA1 and BRCA2, may be involved in the development of prostate cancer. Several studies have screened prostate cancer populations for the presence of BRCA1 and BRCA2 mutations, with few mutations identified. In this study, 22 high-risk prostate cancer families (at least three cases of prostate cancer) were screened by conformation-sensitive gel electrophoresis (CSGE) for mutations in BRCA1 and BRCA2. To maximize the chance of finding mutations in these two genes, families were also selected for the presence of at least two cases of breast and/or ovarian cancer. We identified one previously reported BRCA2 missense mutation and two previously unreported BRCA2 intron polymorphisms. No BRCA1 or BRCA2 truncating mutations were detected. Thus, BRCA1 and BRCA2 appear to have a limited role in familial prostate cancer, and families with both prostate and breast cancer may result from mutations in other predisposition genes.

This article has been cited by other articles:

				H. Schayek, K. Haugk, S. Sun, L. D. True, S. R. Plymate, and H. Werner Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner Clin. Cancer Res., March 1, 2009; 15(5): 1558 - 1565. [Abstract] [Full Text] [PDF]

				I. Agalliu, R. Gern, S. Leanza, and R. D. Burk Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations Clin. Cancer Res., February 1, 2009; 15(3): 1112 - 1120. [Abstract] [Full Text] [PDF]

				J. A. Douglas, A. M. Levin, K. A. Zuhlke, A. M. Ray, G. R. Johnson, E. M. Lange, D. P. Wood, and K. A. Cooney Common Variation in the BRCA1 Gene and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1510 - 1516. [Abstract] [Full Text] [PDF]

				F. J. Couch, M. R. Johnson, K. G. Rabe, K. Brune, M. de Andrade, M. Goggins, H. Rothenmund, S. Gallinger, A. Klein, G. M. Petersen, et al. The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 342 - 346. [Abstract] [Full Text] [PDF]

				I. Agalliu, E. M. Kwon, D. Zadory, L. McIntosh, J. Thompson, J. L. Stanford, and E. A. Ostrander Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer Clin. Cancer Res., February 1, 2007; 13(3): 839 - 843. [Abstract] [Full Text] [PDF]

				H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]

				K. A. Zuhlke, J. J. Madeoy, J. Beebe-Dimmer, K. A. White, A. Griffin, E. M. Lange, S. B. Gruber, E. A. Ostrander, and K. A. Cooney Truncating BRCA1 Mutations Are Uncommon in a Cohort of Hereditary Prostate Cancer Families with Evidence of Linkage to 17q Markers Clin. Cancer Res., September 15, 2004; 10(18): 5975 - 5980. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor in Prostate Cancer Endocr. Rev., April 1, 2004; 25(2): 276 - 308. [Abstract] [Full Text] [PDF]

				D. J. Schaid The complex genetic epidemiology of prostate cancer Hum. Mol. Genet., April 1, 2004; 13(90001): R103 - 121. [Abstract] [Full Text] [PDF]

				A. Liede, B. Y. Karlan, and S. A. Narod Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742. [Abstract] [Full Text] [PDF]

				S. A. Krum, G. A. Miranda, C. Lin, and T. F. Lane BRCA1 Associates with Processive RNA Polymerase II J. Biol. Chem., December 26, 2003; 278(52): 52012 - 52020. [Abstract] [Full Text] [PDF]

				T Ikonen, M P Matikainen, K Syrjakoski, N Mononen, P A Koivisto, A Rokman, E H Seppala, O-P Kallioniemi, T L J Tammela, and J Schleutker BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland J. Med. Genet., August 1, 2003; 40(8): e98 - 98. [Full Text] [PDF]

				J. Simard, M. Dumont, P. Soucy, and F. Labrie Perspective: Prostate Cancer Susceptibility Genes Endocrinology, June 1, 2002; 143(6): 2029 - 2040. [Full Text] [PDF]